Kamiren Xl (Doxazosin)

Doxazosin, the active ingredient in Kamiren Xl, is an Alpha-1 adrenergic blocker presented as an oral tablet for oral use. It treats hypertension and benign prostatic hyperplasia in adult patients. GNH USA supplies Kamiren Xl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Doxazosin belongs to the alpha‑1 adrenergic blocker class and is used to manage conditions related to vascular tone and prostate smooth‑muscle tone. Hypertension: lowers elevated blood pressure by causing peripheral vasodilation, helping to reduce cardiovascular risk. Benign prostatic hyperplasia (BPH): relaxes smooth muscle in the prostate and bladder neck, improving urinary flow and reducing storage symptoms.

Doxazosin may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: light‑headed sensation, often on standing. - Headache: mild to moderate cranial pain. - Fatigue: unusual tiredness or weakness. - Nasal congestion: blocked or runny nose.

Serious or Rare Side Effects: - Severe hypotension: marked blood‑pressure drop that can cause fainting. - Priapism: prolonged, painful erection requiring urgent care. - Allergic reaction: rash, itching, swelling, or breathing difficulty.

When prescribing Doxazosin, clinicians should consider several safety measures. - Monitor blood pressure: check regularly after initiation or dose changes. - Avoid abrupt discontinuation: taper under medical supervision to prevent rebound hypertension. - Caution in hepatic impairment: dose may need adjustment. - Use with caution in patients with a history of orthostatic hypotension. - Review concomitant medications for additive hypotensive effects. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture.

Doxazosin can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Concomitant use with other alpha‑blockers: risk of excessive hypotension. - Potassium‑sparing diuretics (e.g., spironolactone): may enhance hypotensive effect. - CYP3A4 inhibitors (e.g., ketoconazole): increase plasma levels of doxazosin. - Nitrates: additive vasodilatory effect leading to severe hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask tachycardia, monitor heart rate. - Diuretics: may increase orthostatic hypotension, monitor volume status. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy, monitor blood pressure.